FDA Approves IDE Trial of Nerve Stimulation Therapy for Epilepsy

The Monarch eTNS System safely stimulates branches of the trigeminal nerve through the skin. In clinical trials, eTNS has been found to substantially reduce seizures in patients with epilepsy and reduce symptom severity in patients with depression, PTSD and ADHD. Now an IDE study is to start in the US.

NeuroSigma Announces FDA Approval to Commence Phase III Trial (via PR Newswire)

External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy LOS ANGELES, July 29, 2013 /PRNewswire/ — NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration (FDA) of its Investigational Device…

published: July 29, 2013 in: Clinical Studies/Trials, Neuro, Regulatory

Most read

Latest

^